Issuu

2 0 1 9

A N N U A L

R E P O R

SUPPORT FRONTLINE HEROES IN THE SCIENTIFIC REVOLUTION If you would like to support Texas Biomed’s effort to battle COVID-19, please visit www.txbiomed.org/coronavirus TOGETHER, WE CAN MAKE A DIFFERENCE.

2 0 1 9

A N N U A L

R E P O R

BOARD OF TRUSTEES

EXECUTIVE COMMITTEE Dr. James (Jamo) Rubin, Chairman

Mrs. Abigail G. Kampmann

Dr. C. Collins (Andy) Anderson III, Vice Chairman

Mr. John C. Kerr

Mr. James B. (Jamie) Smith, Secretary

Mrs. Marsha M. Shields

President, Signify Community

Managing Partner, Windgate Partners, LLC Vice Chairman – Texas, Dykema Cox Smith Dr. James (Jamo) Rubin Chairman

Managing Director, Sage Energy Co.

Mr. Richard N. Azar II

General Partner, Sezar Energy, L.P.

Mr. Craig Boyan

President & Chief Operating Officer, H-E-B

Mr. Robert M. (Bobby) Cavender President, Cavender Auto Group

Mr. Henry Cisneros

Chairman and CO-CIO, American Triple I Capital

Dr. George Peoples, Jr.

Chief Executive Officer, Cancer Insight, LLC

Mr. Al Rajwani

(Retired) Procter and Gamble

TRUSTEES EMERITUS

Mr. Charles (Chuck) Urschel Slick

Mr. Edward H. Austin, Jr.

Partner, Slick Enterprises

The Honorable Joe Straus III

Principal, La Cima Partners, LLC

Mr. John B. Zachry

Mrs. Barbara B. Dreeben

SPECIAL TRUSTEES

Mr. Walter Embrey

Dr. Taylor Eighmy

President, Slick Enterprises

Chief Executive Officer, Embrey Partners, Ltd.

President, UTSA

Mr. John W. Feik

Dr. Andrea Giuffrida

Mr. Richard Kardys

Vice President for Research and Professor, UTHealth San Antonio

(Retired) Wealth Advisor Senior Officer, Frost Bank

Mr. William R. (Bill) Klesse

Mr. Mark Pitman Mays

Principal, Rocking M Capital Vice Chairman, Broadway National Bank

Dr. Dacia Napier

Principal, Austin Family Investments

Dr. Ronald K. Calgaard

Chairman, Ray Ellison Grandchildren Trust The Abbey

Mr. James W. Gorman, Jr. Investor/Rancher

Mr. William E. Greehey

Chairman, NuStar Energy, L.P.

Mr. John R. (J.R.) Hurd

Chair, Hurd Enterprises, Ltd.

(on behalf of Dr. William L. Henrich)

Mr. Adam L. Hamilton, P.E

President and Chief Executive Officer, Southwest Research Institute

Mrs. Carolyn H. Labatt

Chief Executive Officer, Computer Solutions

(Retired) President/Chief Executive Officer, Project HOPE

President and CAO, Holt Cat

Chairman and Chief Executive Officer, Zachry Group

Chief Executive Officer, Feik Enterprises, LLC

HONORARY TRUSTEE Dr. John P. Howe, III

Mrs. Corinna Richter

Ms. Phyllis Slick Cowell

Entrepreneur

Manager, McCombs Family Partners, Ltd.

Chief Executive Officer, Xeras Medical Technologies

TRUSTEES

Mr. Lewis J. (Lew) Moorman IV

Principal, Moorman Kerr Interests

Mrs. Ashley Hixon

Mr. Rex Amini

Mr. Joe C. McKinney

Chief Executive Officer, Principle Auto

EX-OFFICIO TRUSTEE Mr. Al Philip

Mr. Milton B. Lee

(Retired) Chief Executive Officer, CPS Energy

Mr. B. J. McCombs

Chairman, McCombs Enterprises

Mr. William G. (Bill) Moll

(Retired) Chief Executive Officer, KLRN (Retired) Chairman and Chief Executive Officer, Clear Channel Television

Mr. Richard T. (Dick) Schlosberg III

President, The Argyle

(Retired) Publisher and Chief Executive Officer, Los Angeles Times

Ms. Callie Price

Mr. Edward E. Whitacre, Jr.

President, Founder’s Council

Ms. Amy Swaney

President, Texas Biomedical Forum

Radiologist

Chairman Emeritus, AT&T

CONTENTS

4 6

10 12 14

BETTER OPPORTUNITIES. BETTER SCIENCE.

TEXAS BIOMED’S NEW FACULTY MEMBERS

2019 SCIENCE HIGHLIGHTS

THE VACCINE TIMELINES

15 16 18

SAN ANTONIO PARTNERSHIP FOR PRECISION THERAPEUTICS

FINANCIALS

GRANTS AND CONTRACTS

20 25 27 30 3

PRESIDENT’S LETTER

SCIENTIFIC REVOLUTION CAPITAL CAMPAIGN

CIRCLES OF GIVING

TEXAS BIOMEDICAL FORUM

FOUNDER’S COUNCIL

THE ARGYLE

FROM THE PRESIDENT

Before the Storm: a year of growth and preparation

This culture of collaboration extended well beyond Texas Biomed’s walls in 2019, as we became part of an important collaborative with Southwest Research Institute, UT Health San Antonio and the University of Texas at San Antonio. The San Antonio Partnership for Precision Therapeutics (SAPPT) is a new and unique initiative aiming to capitalize on San Antonio’s bioscience strengths across the four institutions. SAPPT is bringing together earlystage researchers with translational researchers with clinicians and others to create a looped pipeline where information is fed across disciplines so that each stage informs the next and patient data improves and refines basic science and basic science drives better patient outcomes.

write this in the middle of 2020, when it is challenging to reflect back on 2019 — a time that seems so long ago after the events of this year. But, it is important to reflect back to a time when the Institute was sharpening its focus and began the long road toward achieving its 10-year vision of establishing the world’s leading infectious disease research institute. With the Institute’s 10-year strategic plan in its infancy, the team was, in fact, preparing for this very moment in history. The vision to be the go-to place for infectious disease research and development was aided by a concerted and strategic effort in 2019 to grow our people, programs and places, and grow we did. Since 2017, Texas Biomed has added 13 new faculty members. Our new faculty not only bring impressive grant portfolios and significant work on HIV, TB, flu, cancer and other related inflammatory diseases, along with veterinary medicine expertise, they bring with them a plethora of new ideas and a commitment to the Institute’s culture of collaboration, while further fostering our core values of Teamwork, Integrity, Diversity, Excellence and Safety.

The role of research is to inform — to produce data that will inform the development of new diagnostics, therapies and vaccines, which makes our scientists teachers by default. As 2019 was coming to a close, we began hearing about a new virus emerging, and our scientists were spending a great deal of time reading and learning so that we were prepared to be

the science educators our community needed in 2020. We are continuing these teaching moments with a special section in this issue on the vaccine timeline. Our hope is that this timeline underscores the important role preclinical and early stage research done at Texas Biomed plays in the vaccine development process.

None of this teaching and research would be possible without community support. Texas Biomed is fortunate to have so many devoted supporters, who enabled the Institute to open new buildings in 2019, including a brand new BSL-3 laboratory that now houses COVID-19 research — research that would not have been possible without philanthropy for the building. The lab hosted an open house in May 2019, along with tours of a new marmoset housing facility and BSL-4 annex. Our community understands the value of science, and for that, we are eternally grateful. While I can’t predict how the rest of 2020 will play out, I can guarantee that science will be the hero of this story. I leave you with a familiar message, one I shared last year that still rings true today — Science contributes to our understanding of the world around us; it provides comfort and makes life easier; it is a means to an end…healthier lives generation after generation.

SCIENCE CONTRIBUTES TO OUR UNDERSTANDING OF THE WORLD AROUND US; IT PROVIDES COMFORT AND MAKES LIFE EASIER; IT IS A MEANS TO AN END…HEALTHIER LIVES GENERATION AFTER

Larry Schlesinger, M.D. President and CEO

GENERATION.

THE SCIENTIFIC REVOLUTION

Better Opportunities. Better Science.

Dr. Larry Schlesinger, Professor, President and CEO of Texas Biomed. “Our strategic plan sets the framework for us to be a leader in infectious disease research. Through our science and our business model, we have established a new approach to discovery that pushes the boundaries of getting treatments and vaccines from the petri dish to the patient.

exas Biomedical Research Institute (Texas Biomed) launched its 10-year strategic plan in 2018 after a nearly year-long process of developing a comprehensive strategy for growth with a focus on infectious diseases. Constructed with input from faculty and staff members, the Institute’s new direction in establishing a collaborative culture of multidisciplinary research is making strides, and the science community is taking notice. Since the plan has been in motion, the Institute has recruited 13 new faculty members, which has been the driving force behind the Institute’s brand of a world class research facility focused on eradicating infectious diseases.

Of the 13 new recruits joining Texas Biomed, three were welcomed in 2017, two in 2018, three in 2019 and five will join Texas Biomed in 2020. These recruitments not only extend the expertise of Texas Biomed’s scientific staff but also add to the Institute’s capabilities in veterinary medicine and business administration. As the Institute presses on with its strategic plan, senior leaders, faculty members and staff continue to look forward to greater opportunities and enhanced scientific discovery.

“Scientists predict by 2050 infectious diseases will be the number one global killer surpassing heart disease, hypertension and cancer,” said

TEX AS BIOMED’S NEW FACULT Y MEMBERS

2017 RECRUITS LARRY SCHLESINGER, M.D. Professor, President & CEO Dr. Schlesinger is an internationally recognized authority in infectious diseases with a particular interest in tuberculosis and lung biology. As a physician scientist, his studies focus on the pathogenesis of tuberculosis and other airborne infectious agents that subvert lung immune mechanisms.

JOANNE TURNER, Ph.D. Professor and Vice President for Research Dr. Turner ensures Texas Biomed scientists receive the support needed to conduct their science. She also has a lab within the Texas Biomed campus and focuses her research on tuberculosis, aging and inflammation.

JORDI TORRELLES, Ph.D. Professor Focused on the study of the human lung environment and its effect on the outcome of TB disease due to Mycobacterium tuberculosis (M.tb) infection, Dr. Torrelles’ lab has developed a faster and cheaper TB diagnostic test, which is undergoing field testing in the Democratic Republic of the Congo. His team also has a patented TB vaccine candidate.

2018 RECRUITS CORINNA ROSS, Ph.D. Associate Professor Dr. Ross’ laboratory team is developing new phenotypic tools to assess marmoset health and behavior as a biomedical model of human disease. They are also developing new techniques to increase longevity in the marmoset. Improved health and longevity of marmosets is important for future studies of aging processes in nonhuman primate models for the purpose of improving human health. 7

TEX AS BIOMED’S NEW FACULT Y MEMBERS DEEPAK KAUSHAL, Ph.D. Professor and Director of SNPRC As the Director of the Southwest National Primate Research Center, Dr. Kaushal oversees more than $40 million NIH-funded national resources for primate research center. Dr. Kaushal also maintains his own lab focused on studying tuberculosis in nonhuman primate models.

2019 RECRUITS ANNA GOODROE, D.V.M., DACLAM Assistant Professor, Veterinarian Dr. Goodroe has her doctorate in Veterinary Medicine from Texas A&M University. She’s particularly fond of working with marmosets, small New World monkeys from South America used for research in areas from Alzheimer’s to Zika.

DIAKO EBRAHIMI, Ph.D. Assistant Professor Dr. Ebrahimi has more than a decade of experience working in quantitative biology and genomics. His lab combines data and expertise across multiple quantitative and experimental science disciplines such as genetics, virology, cancer, evolution, bioinformatics, mathematics, and statistics to develop and test novel hypotheses.

MAHESH MOHAN, Ph.D. Professor The focus of Dr. Mohan’s laboratory is to investigate epigenetic mechanisms, in particular, the role of microRNAs (miRNAs) and DNA methylation in the molecular pathogenesis of HIV/SIV infection.

2020 RECRUITS LUIS MARTINEZ-SOBRIDO, Ph.D. Professor Dr. Martinez-Sobrido is widely recognized for his expertise in generating recombinant viruses, specifically influenza, arenaviruses, and Zika virus, using plasmid-based reverse genetic approaches. His lab aims to develop vaccines and antivirals that can be long-lasting for viral infections in humans.

CORY HALLAM, Ph.D. Vice President of Business Development and Strategic Partnerships, Professor Dr. Hallam was the force behind the Center for Innovation Technology and Entrepreneurship at the University of Texas at San Antonio (UTSA), serving as its founding director. He was also UTSA’s chief commercialization officer and an associate professor for the Jacobson Distinguished Professorship of Innovation and Entrepreneurship.

DIANA SCORPIO, D.V.M., MPH, DACLAM Professor, Associate Director of Veterinary Resources and Research Support, and Attending Veterinarian Dr. Scorpio is a licensed veterinarian and has been a Diplomate of the American College of Laboratory Animal Medicine since 2004. She was, most recently, the Chief Senior Scientist at the National Institutes of Health.

BINHUA (JULIE) LING, Ph.D. Associate Professor Dr. Ling’s lab focuses on the investigation of persistent HIV tissue reservoirs and development of prophylactic and therapeutic strategies for prevention and cure of HIV-1 infection in humans using a model of simian immunodeficiency virus or simian-human immunodeficiency virus (SIV/SHIV) infection in nonhuman primates (NHP).

VINAY SHIVANNA, Ph.D., D.V.M., DACVM Assistant Professor and Veterinary Pathologist Dr. Shivanna comes from Kansas State University, where he served as an anatomic pathology resident. He is a member of the American College of Veterinary Microbiology and brings with him skills and expertise in virology, molecular biology, molecular pathology and host-pathogen interactions, as well as experience in high containment research. 9

2019 SCIENCE HIGHLIGHTS

iomedical research is moving at a faster pace and has been called “hypercompetitive” by the National Institutes of Health (NIH). Today’s research environment emphasizes the need for effective teams of scientists bringing distinct but complementary approaches to solving big problems, which is exactly how Texas Biomed has approached this time of historical growth and positioned the Institute to respond to the unprecedented challenges the world would face in 2020 in a global race to find a cure and vaccines for the COVID-19 pandemic. Texas Biomed is a successful, private non-profit research institute who has partnered with hundreds of researchers and institutions around the world, targeting advances in the fight against infectious diseases, as well as infectious disease susceptible populations with comorbidities such as aging, diabetes, obesity, and more. Texas Biomed is driven by a daring vision to revolutionize bioscience to drive faster, cheaper, more effective health care innovations to market, specifically in infectious disease care. Discoveries in 2019 helped pave the way for Texas Biomed to grow its capabilities and further solidify its foundation as a critical component for pre-clinical studies that move medicines and technologies to market.

NEW BSL-3 LABORATORY EXPANDS TEXAS BIOMED’S RESEARCH ARSENAL Texas Biomed completed the construction of a new state-of-the-art biosafety level 3 (BSL-3) laboratory and opened its doors to begin research. Dr. Schlesinger said Texas Biomed’s laboratory expansions were crucial to meet the growing

demands for discovering more effective diagnostics, therapies and vaccines for infections. The new BSL-3, along with renovations to the BSL-4 and new marmoset facilities that also came online in 2019, have contributed significantly to Texas Biomed’s ability to play an important role in the 2020 COVID-19 pandemic.

OPTOFLUIDIC CHIPS TO DETECT ZIKA VIRUS The Zika virus, which is caused by the bite from an infected mosquito, has been infecting humans for 70 years. There’s no vaccine for the virus, and pregnant women suffer the worst of symptoms. The virus is known to cause deformities in fetuses and often leads to stillbirths and miscarriages. Texas Biomed has been leading efforts in Zika virus research, as Professor Jean Patterson, Ph.D. has been studying the virus since 2017. Dr. Patterson, along with collaborators from the University of California at Santa Cruz, Brigham Young University and the University of California at Berkeley, developed a new technology using optofluidic chips to screen bodily fluids (blood, urine, semen) for the presence of the virus and determine its stage. Knowing the stage of the virus using this new diagnostic tool may help clinicians treat patients before the virus replicates, causing further damage.

TEXAS BIOMED DEVELOPS QUICK AND AFFORDABLE TB DIAGNOSTIC The world’s highest incidence of Tuberculosis, the disease caused by the virus Mycobacterium tuberculosis, and drug-resistant tuberculosis is within the Democratic Republic of the Congo (DRC). However, testing in the DRC is unparalleled to other countries affected by the 10

FINANCIALS

longevity and healthspan in mice. The scientists are working to receive federal funding for a long-term research project focusing on the effectiveness of the medications.

disease. Alongside worldwide collaborators, Texas Biomed researchers, led by Dr. Jordi Torrelles, Professor and Population Health Program Lead, developed a faster and cheaper diagnostic to test for TB and implemented field testing in the DRC. This will allow patients affected with the disease to have easy access to testing. Researchers continue to collect data from the field tests and hope their efforts will lead to bigger healthcare changes in the DRC such as access to affordable medication.

NEW PARTNERSHIP WITH LONGTIME COLLABORATORS Founded by UT Health San Antonio, Texas Biomedical Research Institute (Texas Biomed), The University of Texas at San Antonio (UTSA) and Southwest Research Institute (SwRI®), the San Antonio Partnership for Precision Therapeutics (SAPPT) is a new San Antonio partnership created to address the specific and diverse medical needs of the city’s population while serving as a model for the development of therapies to improve medical treatment around the world. It includes collaborative research project teams, overseen by a leadership council and external advisory board, as well as a technical steering committee composed of senior technical leads from all four institutions and pharmaceutical and industry experts who guide the selection of projects and commercialization opportunities. Learn more about this unique new organization on page 14.

DIABETES MEDICATION USED TO REVERSE AGING The use of diabetic medications to turn back the clock on aging made headlines. A collaborative study with the Southwest National Primate Research Center (SNPRC), UT Health San Antonio, South Texas Veterans Health Care System and Texas A&M San Antonio showed Metformin and Acarbose had no adverse side effects when given to Marmoset monkeys, which have aging patterns similar to humans. The theory behind these medications’ possible agerelated benefits is that their activity mimics calorie restriction, an intervention shown to increase 11

OPTIMIZING VACCINE DEVELOPMENT TIMELINES: THE TEXAS BIOMED DIFFERENCE

THE RIGHT RESOURCES:

The functionality of highly integrated BSL-3/BSL-4 laboratory capacity, multiple nonhuman primate (NHP) species co-located on campus, and scientific and animal care staff highly experienced at pre-clinical science is unmatched.

OPERATIONAL AGILITY:

Highly networked with sponsors, donors, and the NIH, we coordinate agreements, navigate complex regulatory and compliance processes, and initiate studies faster than traditional commercial or academic R&D organizations.

LASER FOCUS ON EVIDENCE-BASED SCIENCE, SAFETY, AND EFFICACY:

With a secure facility, more than 50 years of infectious disease experience, and the credentials and grit that FDA review and approvals demand, we move quickly and unencumbered through clinical trial phases without sacrificing evidence-based science, the safety of patients, or efficacy of therapeutics.

STEP 1

Basic Discovery Research • Understand the virus: Virologists study the virus through a variety of methods — from genomics to biology. • Understand the immune response: Immunologists look at how our bodies respond to a virus by searching for immune response drivers. • Determine whether the immune response is protective: Researchers perform in vitro (cell culture) and in vivo (animal model) studies to test whether antibodies produced protect the immune system and block virus replication.

STEP 2

Texas Biomed has a team of more than 75 PhD scientists focused on infectious disease research and the intersection of infection and chronic diseases, such as diabetes, heart disease and even aging. This focus enables Texas Biomed to speed the rate of discovery and contribute to greater scientific understanding of the interactions between microbes and humans. This research is the foundation for the medicines we take and the technologies that save human lives.

5-15 YEARS

Pre-clinical Development PART 1: ANIMAL MODEL DEVELOPMENT • Why animal models? o Only humans and other primates are susceptible to many of the infectious diseases that threaten human populations. o Nonhuman primate models allow investigation of physiological characteristics shared only by humans and other primates.

Texas Biomed addresses research questions using cell cultures, tissue studies and computer models, but research with animals is critical for the advancement of human health. Complex disease processes involve multiple physiological processes and organ systems and require the use of complex models. 12

PART 2: VACCINE DEVELOPMENT • Scientists take components of the virus that provide protective immune response and assemble them together, usually one of two ways: 1) using the whole virus (if it is killed to make it noninfectious) or 2) using proteins, RNA or DNA of the virus to make it recognizable. • They then may incorporate adjuvants to see which drive the best immune response. Typically, only a few work in humans, so those are tested first. • The vaccine is then designed and screened through a small animal (like rodents, guinea pigs, ferrets, or rabbits) to determine effectiveness. This is usually conducted several times using control animals to ensure the data is repeated and accurate. • Studies then progress to larger animal models like nonhuman primates to test safety and efficacy ahead of human clinical trials.

STEP 2

(continued)

Pre-clinical Development PART 3: FDA SUBMISSION REQUIREMENTS TO MOVE TO HUMAN CLINICAL TRIALS

5-15 YEARS

• Drug developers, or sponsors, must submit an Investigational New Drug (IND) application to FDA before beginning clinical research. In the IND application, developers must include: o Animal study data and toxicity (side effects that cause great harm) data o Manufacturing information o Clinical protocols (study plans) for studies to be conducted o Data from any prior human research o Information about the investigator

STEP 3

Texas Biomed is home to the Southwest National Primate Research Center, one of seven national centers in the U.S. dedicated to research with nonhuman primates (monkeys). Texas Biomed is also home to rodent and other animal species research and is the only place in the world to combine these animal research resources with the highest biosafety containment labs and regulated study procedures, which enable the Institute to move through pre-clinical development seamlessly and comprehensively, so as to move therapeutics and vaccines through this part of the pipeline faster. • These plans must adhere strictly to quality control and assurance standards, and provide proof of scientific validity and reproducibility. • The FDA team requires a 30-day timespan for review in an effort to keep volunteers safe and avoid significant risk.

Clinical Development

2-5 YEARS

PART 1: CLINICAL TRIALS Over the course of several years, thousands of human patients must be tested before the FDA will grant national approval for a commercialized pharmaceutical product, based on the following phases: • Phase 1: 20-119 volunteers with no underlying health conditions are tested to find the best dose of a new drug with the fewest side effects. This phase is largely focused on safety for use. • Phase 2: 100-500 volunteers with the disease or condition being studied are tested to determine the drug’s effectiveness and to outline the common short-term adverse effects and risks associated with the drug.

STEP 4

• Phase 3: 1000-5000 volunteers with the disease or condition being studied are tested to evaluate how the new medication works in comparison to existing medications for the same condition. Trials in this phase can last for several years. PART 2: FDA APPROVAL PROCESS The FDA’s drug approval process includes: • Analysis of the target condition and available treatments • Assessment of benefits and risks from clinical data • Strategies for managing risks • Approvals can be expedited for serious and life-threatening conditions; however, approvals generally take between 6 and 10 months

Commercial Phase

1-2 YEARS

Before commercialization of a vaccine can begin, the FDA requires: • FDA approval of the drug for commercialization based upon pre-clinical and clinical study data • Production of label and description

STEP 5

• Regulatory review & approval, including fair market pricing • Submission of a Biologics License Application (BLA), a request to introduce or deliver a biologic product into interstate commerce, which takes 6-10 months for approval From there, companies may commercially market their release of the vaccine.

Manufacturing Scale-up The fastest a vaccine has ever been made is 5 years, and the manufacturing process typically takes between 6 and 36 months. The process includes propagation of virus in bulk, purification, clarification, formulation (adding safe stabilizers and preservatives), and quality control through several hundred test processes.

STEP 6

Distribution to Providers & Patients Once large-scale manufacturing is established, the vaccines can then be packaged, batch released, transported and distributed/shipped to healthcare providers. 13

CO LL ABO R AT I O N MOV ES SCIENCE FO RWAR D FA S T ER

Health San Antonio (William Henrich) and the University of Texas at San Antonio (Taylor Eighmy) decided that the collaborations already in existence, such as the Vaccine Development Center of San Antonio, were a great starting point for a bigger effort that would solidify San Antonio as a place where science is thriving. What San Antonio needed was an organization to advance high-impact biomedical research in such a way that improved the health of San Antonio’s diverse population and served as a model for how science could move forward faster — enter the San Antonio Partnership for Precision Therapeutics (SAPPT).

he entrepreneurial spirit continues to grow in San Antonio and has a strong foothold in the city’s bioscience sector. What the city lacks in size for this industry, it is making up for in collaboration — an asset so unique that cities nationwide are trying to emulate, as evidenced by a 2019 visit from the Indianapolis Chamber of Commerce that included several roundtables and workshops focused on San Antonio’s united bioscience culture. “When I came to San Antonio in 2017, I quickly realized the distinctiveness of this community and the opportunity to build something extraordinary with the community’s spirit of collaboration,” said Dr. Larry Schlesinger, President/CEO of Texas Biomed. “The prospect of a small, independent research institution combining forces with undergraduate, graduate and independent research entities in the city is San Antonio’s competitive advantage.”

“Precision therapeutics allows us to tailor our treatments from person to person, adapting for a patient’s lifestyle, environment and biology, within and across patient populations,” said Texas Biomed President and CEO Larry Schlesinger, M.D. “What is most exciting is that this program will completely integrate the approach of precision medicine with the discovery of new treatments as well as the reformulation of existing drugs and drug combinations to address the growing drug resistance problem. It’s a

Over a glass of wine and good conversation, the presidents of Southwest Research Institute (Adam Hamilton), Texas Biomed (Larry Schlesinger), UT

Clinical Trials/ FDA Approval

Testing/ Animal Models

Breakthrough Treatment

Individualized Treatment

Monitoring of Patient Populations

Big Data Integration

Basic Research

Measurements & Analytics

Drug Discovery

Patient Proﬁles

FINANCIALS

2019 REVENUE

40.5% 0.8% 11.6% 1.9% 0.1%

Federal Grants Non-Federal Grants Federal Contracts Commercial Contracts Non-Federal Contracts

19%

Restricted Contributions

3.1% 21.6% 1.1% 0.3%

Unrestricted Contributions Investment Income Royalty Income Other Income

BASED ON 2019 AUDITED REPORT

$130

$125.1 $117.4 $118.3

$120

$111.5

2019 VALUE OF ENDOWMENT IN MILLIONS OF DOLLARS

$114.7

$114.6 $107.2

$100.8

$100 $93.2

$91.4

$80

$60

2010

2011

game-changing approach to health care that will allow us to more quickly get therapies to market and work for the majority of those who need it most.”

The goals of SAPPT are to improve medicine by delivering therapies faster, with shorter recovery times and life-saving options tailored to individual populations rather than the masses. The work of SAPPT is being developed on the foundation of a $40 billion bioscience industry in addition to military medical research that will provide a collaborative opportunity unique to San Antonio. Funded with startup monies from each of the four institutions, SAPPT has established a scientific advisory board and already funded several projects

2012

2013

2014

2015

2016

2017

2018

2019

through 2020. Additional support will help sustain the organization as it grows, as evidenced by donations in 2020 from USAA, the San Antonio Area Foundation, the Vaccine Development Center and organizational support from the San Antonio Economic Development Foundation. Liz Tullis, SAPPT Director, added, “Our community is diverse and can serve as a microcosm of the nation. This collaboration is a way to integrate what is learned at the bedside with what is learned in the lab to create more precise therapies for a wider range of populations. Ultimately, through SAPPT, San Antonio has the opportunity to create a world-class research hub for individualized health care.” 15

R E S E A R C H G R A N T S & CO N T R AC T S AWA R D E D I N 2019

FEDERAL RESEARCH GRANTS

PRINCIPAL INVESTIGATOR

LENGTH

PROJECT TOTAL

NATIONAL INSTITUTES OF HEALTH (NIH) – Establishment of a SPF Rhesus Macaque Colony

Dr. Deepak Kaushal

4 years

$9,299,924

NIH – Cold Chain-Independent, Needle-Free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels

Dr. Viraj Kulkarni

2 years

$8,120,959

NIH – SigH based attenuated, efficacious M.tb vaccines to protect against lethal TB

Dr. Deepak Kaushal

4 years

$4,214,613

NIH – Impact of concurrent HIV and latent TB therapies on Mtb-specific immune function

Dr. Deepak Kaushal

3 years

$3,299,986

NIH – Immune Correlates of Protection from TB

Dr. Deepak Kaushal

4 years

$3,237,501

NIH/UOHSC – Strong Heart Study Coordinating Center

Dr. Shelley Cole

6 years

$3,097,542

NIH – Macrophage nuclear receptors, metabolism and immune effectors during health and M. tuberculosis infection

Dr. Larry Schlesinger

4 years

$2,856,798

NIH/STONYBROOK U – Cannabinoid modulation of extracellular vesicle composition and function in HIV/SIV infection

Dr. Mahesh Mohan

5 years

$2,315,013

NIH/HMRI – A Neonatal Monkey Model of Tuberculosis Vaccination

Dr. Marie-Claire Gauduin

3 years

$2,251,269

NIH/BCH – Optimizing and preclinical development of a TB Multiple Antigen Presenting System (MAPS) vaccine

Dr. Deepak Kaushal

4 years

$1,532,253

CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAM – Zika Virus Countermeasures: Preclinical Pregnancy Models to Assess Protective Efficacy Against Placental Damage and Fetal Demise

Dr. Jean Patterson

3 years

$1,233,890

NIH – Perturbation of antigen-specific T cell responses in latent TB/SIV co-infection

Dr. Deepak Kaushal

2 years

$1,077,111

NIH/TRINITY – Marmosets as a Model for Understanding Social, Neuroendocrine, and Vascular Contributions to Cognitive Aging

Dr. Corinna Ross

5 years

$701,089

NIH/UWASH – Role of Group 3 Innate Lymphoid cells (ILC3) in Tuberculosis

Dr. Deepak Kaushal

4 years

$645,830

NIH/TULANE – Impact of tuberculosis on the development and function of the immune system in SIV-infected infants

Dr. Deepak Kaushal

5 years

$614,381

NIH/WUSL – Role of inducible bronchus associated lymphoid tissue in latent Tuberculosis

Dr. Deepak Kaushal

2 years

$561,462

NIH/UCSC – Nanopore-based multi-target analysis of Zika virus infection

Dr. Jean Patterson

4 years

$508,195

NIH – Expansion of Marmoset Breeding Facilities to Meet Increasing Research Demands (SNPRC Supplement)

Dr. Larry Schlesinger

1 year

$499,999

NIH – Role of chronic immune activation reactivating latent tuberculosis infection during M. tuberculosis/SIV co-infection: implications for anti-retroviral and anti-TB therapies (SNPRC Supplement)

Dr. Larry Schlesinger

2 years

$499,998

NIH – Development of resources to assess ambulation and sensory systems for marmoset AD/dementia research (SNPRC Supplement)

Dr. Corinna Ross

1 year

$423,597

NIH/WUSL – Common immune correlates of risk of TB disease in animal models and humans

Dr. Deepak Kaushal

3 years

$290,964

NIH – Exploring the impact of inflammaging on immune function during M. tb infection (Admin Supplement)

Dr. Joanne Turner

1 year

$289,900

NIH/EMORY – Role of Antigen Specific T Cell Responses in the Control of TB

Dr. Deepak Kaushal

3 years

$287,231

NIH/WUSOM – Population genomics and new tools for the endgame of onchocerciasis elimination in Africa

Dr. Timothy Anderson

5 years

$254,786

BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY/JANSSEN – ELIspot and ICS analysis of Non-Human Primate samples generated under Janssen (DS-REF-129289: Immunogenicity of SLA-LSQ adjuvant formulations in non-human primates)

Dr. Luis Giavedoni

1 year

$223,697

SPONSOR AND TITLE

PRINCIPAL INVESTIGATOR

LENGTH

NIH/IOWA – CD40 regulation of acute virus infection

Dr. Olena Shtanko

2 years

$125,794

NIH – 37th Annual Symposium on Nonhuman Primate Models for AIDS

Dr. Luis Giavedoni

1 year

$74,999

NIH/JANSSEN – Janssen Federal Work Orders – Giavedoni; EBOV Vaccine study 17 ELISPOT

Dr. Luis Giavedoni

1 year

$67,971

DEFENSE THREAT REDUCTION AGENCY/SRI – Grow, Expand, and Extract Total RNA

Dr. Ricardo Carrion

1 year

$62,192

NIH/EMORY – Development of Gleevec for TB and TB/HIV

Dr. Deepak Kaushal

2 years

$59,005

NIH/UTHSCSA – Evaluation of the risk of TB reactivation in BCG vaccinated marmosets treated with IL-17 antagonist, Secukinumab

Dr. Deepak Kaushal

1 year

$45,000

NIH/AiBS – Novel accurate therapy for Multiple Sclerosis: Optimization of antisense oligonucleotides delivery and functionality in primary T cells

Dr. Corinna Ross

2 years

$23,162

NIH/UPMC – Regulatory immune cell therapy, promotion of tolerance and underlying mechanisms in NHP renal transplantation Luminex assay (29-plex)

Dr. Luis Giavedoni

1 year

$9,526

NIH/UTMB – Screening EBOV ELISA assay for 30 cynomolgus samples from Covance for UTMB

Dr. Luis Giavedoni

1 year

$7,470

SPONSOR AND TITLE

PROJECT TOTAL

Total from Federal Research: $48,813,107 PHILANTHROPIC AND PRIVATE CONTRACTS AND GRANTS SPONSOR AND TITLE

PRINCIPAL INVESTIGATOR

LENGTH

PROJECT TOTAL

SAN ANTONIO MEDICAL FOUNDATION – Modified Mycobacterium bovis Calmette-Guerin vaccine to improve bladder cancer Dr. Jordi Torrelles

1 year

$173,354

CIVILIAN RESEARCH AND DEVELOPMENT FOUNDATION GLOBAL – Immune and microbiome correlates of TB reactivation in PLHIV and a NHP model

Dr. Deepak Kaushal

3 years

$120,000

WILLIAM & ELLA OWENS MEDICAL RESEARCH FOUNDATION – Reversing age-related cognitive decline and memory deficits with mitochondria enhancers

Dr. Marcel Daadi

3 years

$101,708

OTTAWA HOSPITAL RESEARCH INSTITUTE – Umbilical Cord Stem Cell Therapy for Bronchopulmonary Dysplasia

Dr. Christopher Chen

1 year

$81,993

TEXAS BIOMEDICAL FORUM – Population-specific immune gene splicing and its role in antiviral immunity

Dr. Diako Ebrahimi

1 year

$60,000

TEXAS BIOMEDICAL FORUM – Linking receptor-mediated phagocytosis and cAMP pathways in macrophage responses to Tuberculosis

Dr. Chrissy Leopold Wager

1 year

$60,000

TEXAS BIOMEDICAL FORUM – CRISPR/Cas13d RNA editing system: A new scissor to clip HIV RNA

Dr. Viraj Kulkarni

1 year

$60,000

PhRMA FOUNDATION/PURDUE – Integrating in vitro and computational approaches to accelerate drug development for TB/HIV co-infection

Dr. Larry Schlesinger

2 years

$27,735

Total from Philanthropic and Private Research: $684,790 COMMERCIAL CONTRACTS

Total from Commercial Research: $190,727 TOTAL OF NEW CONTRACTS AND GRANTS: $49,688,624

S C I E N T I F I C R E V O L U T I O N C A P I TA L C A M PA I G N

Thank You.

Last year, Texas Biomed embarked on a Scientific Revolution Capital Campaign. This 10-year strategic plan is a bold pathway to defeat infectious disease supporting three initiatives: people, programs, and places. With appropriate recruitment of top tier scientists, support systems to ensure cutting-edge success, and innovative spaces, Texas Biomed is positioned to become a world leader in infectious disease research. This is made possible through the philanthropic support of donors committed to the mission and who share the vision of Texas Biomed. 18

Mr. and Mrs. Rex Mitchell Amini Mr. Charles C. Butt The Ewing Halsell Foundation H-E-B

Kerr Family Charitable Foundation and Mr. and Mrs. John C. Kerr

Mr. and Mrs. Stephen Goebel

Lyda Hill Philanthropies

Ms. Jane Ballantyne Hegeler

Ms. M. Sue Marmion Mary A. Peterson Wyatt Charitable Trust

Klesse Foundation Mr. and Mrs. William R. Klesse Kronkosky Charitable Foundation Mays Family Foundation Valero Energy Foundation

McCombs Foundation Mr. and Mrs. Lewis J. Moorman IV Mr. Albert Lanham and Dr. Dacia Napier National Institutes of Health Mr. and Mrs. John “Chico” Newman Phoenix Charitable Foundation Dr. and Mrs. Jamo Rubin

80|20 Foundation Amy Shelton McNutt Charitable Trust Dr. and Mrs. C. Collins Anderson III Betty Stieren Kelso Foundation Mr. and Mrs. Craig Boyan Mr. and Mrs. Robert M. Cavender

Mr. Richard T. Schlosberg III and Dr. Kathy Schlosberg The Slick Family Foundation USAA Foundation V. H. McNutt Memorial Foundation

Mr. and Mrs. Walter Embrey, Jr. The Ewing Halsell Foundation Texas Biomedical Forum Frost Bank Charitable Foundation Gorman Foundation and Mr. and Mrs. James W. Gorman, Jr. Mr. and Mrs. Jack Guenther Holt Family Foundation Mr. and Mrs. John R. Hurd Mr. and Mrs. George A. Kampmann, Jr. Mr. and Mrs. Richard Kardys

Herrmann-Zeller Foundation Mr. and Mrs. Roger C. Hill, Jr. 2011 Eric Hill Gift Trust Mr. and Mrs. Timo Hixon J & M Rubin Foundation Joan and Herb Kelleher Charitable Foundation Mr. and Mrs. Luke C. Kellogg Mr. and Mrs. Robert A. Kiolbassa Mr. and Mrs. Joseph B. Labatt Mr. and Mrs. Cappy Lawton Ms. Ann Marmion Mr. James R. Marmion III Mr. and Mrs. Alexander S. McAllister Mr. and Mrs. Joe C. McKinney Anonymous Donor

Ms. Phyllis Slick Cowell Mr. and Mrs. Alan W. Dreeben

Mr. and Mrs. Michael Harper

Mr. and Mrs. Edward H. Austin, Jr. Mr. and Mrs. Richard N. Azar II The Brown Foundation, Inc. Mr. and Mrs. John Brozovich Mr. and Mrs. Charles E. Cheever, Jr. Mr. Chris Cheever The Honorable Henry Cisneros and The Honorable Mary Alice Cisneros Mr. and Mrs. Rex Duhn Mr. and Mrs. Donald G. Elliott Mr. and Mrs. John W. Feik Mr. and Mrs. Hugh A. Fitzsimons, Jr.

Mr. and Mrs. Ted Paup Mr. and Mrs. Al Rajwani Richard Spencer Lewis Memorial Foundation Ms. Roxana McCallister Richardson Mr. and Mrs. J.B. Richter San Antonio Area Foundation Mr. and Mrs. Robert J. Schupbach The Honorable and Mrs. John Shields Mr. Charles Urschel Slick Mr. Charles U. Slick, Jr. Mr. and Mrs. James B. Smith, Jr. Ms. Ann Brennand Watson

*ALONGSIDE OTHER SCIENTIFIC REVOLUTION CAPITAL CAMPAIGN SUPPORTERS TOTALING $103,000 IN SUPPORT OF OUR MISSION.

CIRCLES OF GIVING

Unraveling the Mysteries of Infectious Disease Together Thank you for being a part of discoveries giving hope to millions worldwide.

CHAIRMAN’S CIRCLE

Mr. and Mrs. J. Bruce Bugg, Jr.

Mr. and Mrs. John W. Feik

2011 Eric Hill Gift Trust

Mr. Charles C. Butt

Mr. and Mrs. Ron Finch

4L Oilfield Services, LLC

Mr. and Mrs. Robert M. Cavender

The Fletcher Jones Foundation

80/20 Foundation

Mr. and Mrs. Charles E. Cheever, Jr.

Founder’s Council

Mr. and Mrs. Rex Mitchell Amini

Mr. Chris Cheever

The Frost Bank Charitable Foundation

Amy Shelton McNutt Charitable Trust

The Honorable Henry Cisneros and The Honorable Mary Alice Cisneros

Mr. and Mrs. Joseph W. Gorder

Ms. Phyllis Slick Cowell

Mr. and Mrs. James W. Gorman, Jr.

Mr. and Mrs. Edward H. Austin, Jr.

Mrs. James L. Donnell

Mr. and Mrs. Jack Guenther

Mr. and Mrs. Richard N. Azar II

Douglass Foundation

Jack and Valerie Guenther Foundation

Mr. and Mrs. Sam P. Bell, Jr.

Mr. and Mrs. Alan W. Dreeben

Mr. and Mrs. Curtis C. Gunn, Jr.

Bennie W. Schreck Charitable Trust

Mr. and Mrs. Rex Duhn

Gunn Family Foundation

Betty Stieren Kelso Foundation

The Edouard Foundation, Inc.

Mr. and Mrs. Frederic Hamilton

Biglari Foundation

Mr. Donald G. Elliott

Mr. and Mrs. Michael Harper

Mr. and Mrs. Craig Boyan

The Ellwood Foundation

The Harris K. & Lois G. Oppenheimer Foundation

La Brasada Foundation

Mr. and Mrs. Walter Embrey, Jr.

H-E-B

The Brown Foundation, Inc.

The Ewing Halsell Foundation

Hermann-Zeller Foundation

Mr. and Mrs. Robert A. Anderson Dr. and Mrs. C. Collins Anderson III

Gorman Foundation

Mr. and Mrs. Roger C. Hill, Jr.

Mr. Charles G. Northrup

PRESIDENT’S CIRCLE

Mr. and Mrs. George “Timo” Hixon

Anonymous Donor

Mr. and Mrs. Edgar A. Basse III

Hixon Properties, Inc.

Mrs. Claire Oppenheimer O’Malley

Ms. Jean Cheever

Holt Family Foundation

Phoenix Charitable Foundation

Dr. Robert R. Clemons

Mr. and Mrs. John R. Hurd

Mr. and Mrs. Al Rajwani

Mr. and Mrs. Peter B. Dahlberg

J & M Rubin Foundation

Mrs. Judy Renick

Mr. and Mrs. Trey Dawson

Joan and Herb Kelleher Charitable Foundation

Richard Spencer Lewis Memorial Foundation

Mr. and Mrs. Jonathan Dear

Mr. and Mrs. William A. Johnson

Ms. Roxana McCallister Richardson

Mr. H. Rugeley Ferguson, Jr.

Mr. Walter Juliff

Mr. and Mrs. J.B. Richter

Mr. and Mrs. Hugh Fitzsimons, Jr.

Mr. and Mrs. George A. Kampmann, Jr.

Dr. and Mrs. Jamo Rubin

Mr. William Ford

Mr. and Mrs. Richard Kardys

Rugeley Ferguson Foundation

Mr. and Mrs. Stephen Goebel

Mrs. Herbert D. Kelleher

Ruth Chapman Cowles & Andrew G. Cowles Memorial Fund

Mr. and Mrs. Joe N. Haynes

Mr. and Mrs. Luke C. Kellogg Mr. and Mrs. John C. Kerr Kerr Family Charitable Foundation Klesse Foundation Mr. and Mrs. William R. Klesse Kronkosky Charitable Foundation Mr. and Mrs. Joseph B. Labatt Lanward Foundation, Inc. Mr. and Mrs. Cappy Lawton Mr. and Mrs. Steven Q. Lee Lyda Hill Philanthropies Mr. Michael Joseph Lynd, Jr. Mr. and Mrs. Clark R. Mandigo II Ms. M. Sue Marmion Mary A. Peterson Wyatt Charitable Trust Mr. and Mrs. Mark P. Mays Mays Family Foundation Mr. and Mrs. Alexander S. McAllister

The Ruth and Edward Austin Foundation RWM Foundation San Antonio Area Foundation Mr. Richard T. Schlosberg III and Dr. Kathy Schlosberg Mr. and Mrs. Robert J. Schupbach The Honorable and Mrs. John Shields Slick Enterprises, Inc. Mr. Charles Urschel Slick Mr. Charles U. Slick, Jr. The Slick Family Foundation Mr. and Mrs. Jack J. Spector Mrs. Louis Stumberg Texas Biomedical Forum Tim and Karen Hixon Foundation The Tobin Endowment USAA Foundation V. H. McNutt Memorial Foundation

Ms. Jane Ballantyne Hegeler Mr. and Mrs. John L. Hendry III Mr. and Mrs. Reagan Houston IV Mr. and Mrs. John R. Hurd, Jr. Mr. and Mrs. Robert A. Kiolbassa Mr. Samuel E. Maclin Ms. Ann Marmion Mr. James R. Marmion III Mr. and Mrs. Robert S. McClane Mr. and Mrs. Robert L. Myers IV Mr. and Mrs. George Parker, Jr. Mr. and Mrs. Allan G. Paterson Mr. and Mrs. Ted Paup Mr. and Mrs. Scott Petty, Jr. Mr. and Mrs. S. Van Stewart Dr. and Mrs. Norton A. Stuart III Louis H. and Mary Patricia Stumberg Foundation

Valero Energy Foundation

Mr. Dale W. Tremblay and Dr. Sandra Tremblay

Ms. Ann Brennand Watson

Dr. Joanne Turner and Dr. Jordi Torrelles

Mr. and Mrs. Edward C. Welsh

Mr. and Mrs. Richard Wade

Mr. and Mrs. Graham Weston

Mr. and Mrs. Warren S. Wilkinson, Jr.

Mr. and Mrs. Lewis J. Moorman IV

William and Ella Owens Medical Research Foundation

Mr. and Mrs. Forrest R. Word

Mrs. Judith N. Morton

The Honorable and Mrs. W. Reed Williams

The Nancy Smith Hurd Foundation

Mr. and Mrs. John B. Zachry

Mr. B. J. McCombs McCombs Foundation McCrea Foundation Mr. and Mrs. Joe C. McKinney Mrs. Lewis J. Moorman III

Tim and Suzanne Word Foundation Mr. and Mrs. James P. Zachry

Nelson Puett Foundation The Nordan Trust

CONTINUED ON PAGE 22

CIRCLES OF GIVING

CONTINUED FROM PAGE 21

BENEFACTOR’S CIRCLE

Minnie Stevens Piper Foundation

Mr. and Mrs. J. Dan Bates

Advantage Pain Management

Project Control of Texas, Inc.

BB&T

Asel & Associates, PLLC

Dr. Carl F. Raba, Jr.

Mr. and Mrs. J. Scott Beckendorf

Mr. and Mrs. John C. Asel

Dr. and Mrs. Frank C. Sammis III

Mr. and Mrs. Brian Beem

The Bank of San Antonio

Mr. and Mrs. J. Thomas Schmidt

Mr. and Mrs. Jonathon Beitz

Mr. and Mrs. James Hunter Barrow

Silver Eagle Distributors, L.P.

Mr. and Mrs. Michael D. Beldon

Mr. and Mrs. Jim Baxter

Mr. and Mrs. Bruce A. Smith

Mrs. Marion Dewar Bell

Mr. and Mrs. Michael L. Benedum

Mr. and Mrs. J. Dudley Snyder

Mr. Matthew M. Bell

Mr. Jeffrey H. Berler

SpawGlass

Mr. and Mrs. Sam P. Bell, Jr.

Brown & Ortiz, P.C.

Texas Medical Legal Consultants, LLC

Ms. Brooke Benson

Dr. and Mrs. Bryce Chandler

Mr. and Mrs. Ty Thaggard

Mr. and Mrs. Ryan Berg

Dr. Sarah Trampota Conquest and Mr. Andrew Conquest

Mr. and Mrs. John C. Thomas

Mr. and Mrs. David Berndt

MW Construction

Mr. and Mrs. Mark J. Berridge

Mr. William R. Crow, Jr.

Worth & Associates

Mrs. Lawrence A. Bertetti

Mr. and Mrs. Jeff and Susan Edwards

Mr. and Mrs. Keith Zars

Eugenia and Lawrence A. Bertetti Foundation

Mr. Robert H. Finney and Dr. Nancy A. Finney

Mr. and Mrs. Thad W. Ziegler

Mr. and Mrs. Albert M. Biedenharn III Mr. and Mrs. Lawrence T. Biedenharn

Mr. and Mrs. Phillip D. Green

GOLDEN CIRCLE

Mrs. Helen Kleberg Groves

Mr. and Mrs. James Ahern

Guido Construction

Mr. Edward L. Block, Jr.

Mr. and Mrs. Frank Aldridge

Mr. and Mrs. Harry Halff

Ms. Donna Block

The Honorable and Mrs. Clyde H. Alexander

Mr. and Mrs. Benjamin B. Holliday

Ms. Margery L. Block

Mr. and Mrs. Curtis Vincent Anastasio

Joeris Construction

Mr. and Mrs. Gregory Bolner

Mr. and Mrs. Stewart L. Armstrong

Mr. and Mrs. Marrs McLean Bowman

Dr. and Mrs. Gary Koehl

Mr. and Mrs. Walter N. Armstrong

Dr. and Mrs. Warren B. Branch

Mr. and Mrs. John C. Korbell

Mr. and Mrs. Douglas Arnold

Dr. and Mrs. Dolph Briscoe IV

Mrs. Elizabeth Tomasovic LaBarge, Esq.

Articulate Strategic Communications

Broadway Bank Wealth Management

Mr. and Mrs. Mike MacNaughton

Mr. and Mrs. Aaron Asel

Mr. and Mrs. James C. Browning

Mauze Construction

Dr. and Mrs. Wilbur S. Avant, Jr.

Mr. and Mrs. John Brozovich

Mr. and Mrs. David Mauze

Mrs. Robert M. Ayres, Jr.

Mr. and Mrs. James H. Bryan, Jr.

Mrs. John McLaughlin

Mr. and Mrs. Richard N. Azar III

Mrs. George V. Burkholder

McNelis + Associates, PLLC

Mr. and Mrs. Michael A. Bacon

Mrs. Walter J. Buzzini III

Mr. and Mrs. Sean B. McNelis

Mr. and Mrs. Edward Badouh III

Mr. and Mrs. A. H. Cadwallader IV

Mr. and Mrs. William G. Moll

Mr. and Mrs. Bertrand Baetz, Jr.

Mr. and Mrs. Presnall Cage

Mr. and Mrs. Edward D. Moore

Mr. and Mrs. Jeff P. Bailey

Mr. and Mrs. T. Randall Cain

Mr. and Mrs. Thomas I. O’Connor III

Mr. and Mrs. James L. Baldwin, Jr.

Dean Charles E. Cantu

Mr. and Mrs. Alex H. Oliver

Mr. and Mrs. Stephen P. Ballantyne

Dr. and Mrs. Carlos Cardenas

Pape-Dawson Engineers, Inc.

Mr. Bruce B. Barshop

Cardno Structural Engineers

Mr. and Mrs. John Carroll Park

Bartlett Cocke General Contractors

Mrs. Cassandra C. Carr

Mrs. William A. Parker

Mr. and Mrs. Sam Collier Bashara

Mr. and Mrs. Pedro Cerisola

Mr. and Mrs. Gardner Peavy

Mr. and Mrs. Lee M. Bass

Mrs. Alfonso Chiscano

Mr. and Mrs. Michael L. Birnbaum

Mr. and Mrs. Corbett Christie

Mr. and Mrs. Chase Gorman

Mr. and Mrs. Pete LaBonte

Mr. and Mrs. James F. Clingman, Jr.

Mr. and Mrs. John Paul Gould

Ms. Carolyn C. Landrum

Mr. and Mrs. Norborne P. Cole, Jr.

Mr. and Mrs. Claiborne B. Gregory, Jr.

Mr. and Mrs. Daryl L. Lansdale, Jr.

Mr. and Mrs. James W. Collins

Mr. and Mrs. Bruce E. Grossman

Mr. and Mrs. Clint Lawson

Mr. and Mrs. Craig Comeaux

Mrs. Burton E. Grossman

Mrs. George J. Condos

Mr. and Mrs. Robert R. Grusky

Mr. Trevor Lawton and Ms. Amy Stinson

Maj. Gen. (Ret.) and Mrs. Hugh L. Cox III

Mr. Hal Joseph Guggolz

Mr. and Mrs. Michael Cruz

Mr. and Mrs. Cosmo M. Guido

Mr. and Mrs. James R. W. Daniell

Mr. and Mrs. Thomas L. Guido

Ms. Susan Kay Davidson

Mr. and Mrs. Robert Gurwitz

Mr. and Mrs. Trey Dawson

Mr. and Mrs. Mark Hanrahan

Mr. and Mrs. Jeffrey de Rojas

Mr. and Mrs. Warren B. Hart II

Mrs. Leroy G. Denman, Jr.

Robert Tucker Hayes Foundation

Mrs. Elizabeth N. Dewar

Mr. and Mrs. Jeffrey E. Heinke

Mr. and Mrs. Michael Dewar

The O’Kelley-Hemminghaus Foundation

Mr. and Mrs. Robert L. Dewar

Mr. and Mrs. Peter J. Hennessey III

Mr. and Mrs. Albert Dickson

Mr. and Mrs. David S. Herrmann

Mr. and Mrs. Blackstone Dilworth

Mr. Jonathan Hess

Mr. and Mrs. Walter D. Downing, Jr.

Mr. and Mrs. Charles R. Hollimon

Mr. and Mrs. William E. Dreyer

Ms. Juana E. Hollin-Avery

Mrs. Betty Ann Ebrom

Mr. and Mrs. Albert Honigblum

Mrs. James A. Elkins III

Mr. and Mrs. Mark S. Howard

Ms. Doris Ellis

Mr. and Mrs. Michael Howard

Mr. and Mrs. James D. Ellis

Mr. and Mrs. Dan Allen Hughes, Jr.

Mr. and Mrs. Trey Embrey III

Mr. and Mrs. Andrew Hunt

Mr. and Mrs. Richard W. Evans, Jr.

Ms. Sara Smith Hurd

Mr. and Mrs. John W. Feik, Jr.

Mr. and Mrs. Kenneth M. Jastrow II

First-Citizens Bank & Trust Company

Dr. Johnny Clay Johnson

Mr. and Mrs. W. W. Flannery, Jr.

Mr. and Mrs. Mark M. Johnson, Jr.

Mr. and Mrs. Edward C. Flato

Mr. and Mrs. Tony C. Johnson

Mr. Charles A. Forster

Mrs. Joe Warren Jones

Mrs. Charles E. Foster

Mr. and Mrs. Patrick J. Kennedy

Mr. and Mrs. Jimmy I. and Nita T. Frank

Mr. and Mrs. Patrick J. Kennedy, Jr.

Mr. and Mrs. Carl “Triple” Fuhrmann

Mr. and Mrs. Creston A. King III

Mr. and Mrs. Charles B. Fulton

Mr. Shaj and Dr. Avina Kolareth

Mr. and Mrs. Craig J. Garansuay

Mr. and Mrs. Bart Koontz

Gary and Sheila Arthur Family Charitable Fund

Mr. and Mrs. Gregory W. Kowalski

Mr. and Mrs. George A. Geis

Ms. Rosemary Kowalski

Mr. and Mrs. Evan and Renee Gerald

Mr. Michael L. Kreager

Dr. and Mrs. William W. Gordon

Mr. and Mrs. William Jeffrey Kuhn

Mrs. Frank F. Ledford, Jr. Mr. and Mrs. Byron L. LeFlore, Jr. Mr. and Mrs. Ralph Lehr, Jr. Mr. and Mrs. Robert R. Lende Mr. and Mrs. Thomas Robert Leslie IV Mr. and Mrs. Steve C. Lewis Mr. Rick Liberto Ms. Joyce Lindler Mr. and Mrs. David G. Lloyd, Jr. David and Letty Lew Lloyd Family Charity Fund Dr. and Mrs. Fernando Lopez Mr. and Mrs. Porter Loring III Mr. and Mrs. Howard H. Lutz Mr. and Mrs. Glenn MacTaggart Mr. and Mrs. Gregory Mann Mr. and Mrs. Madison C. Marceau Mr. and Mrs. Chris Marco Mr. Paul Martin Mr. and Mrs. Ben Mathews Mr. and Mrs. George G. Matthews Mr. and Mrs. John K. Matthews Mr. and Mrs. Madison Mauze Drs. Paul and Christine Mayer Mr. and Mrs. Jess Mayfield Mr. and Mrs. Chance Mazurek Mr. and Mrs. Dan McCarty Mr. and Mrs. Don B. McDonald, Jr. Ms. K. Heather McFarlin Mr. and Mrs. Elkin McGaughy Mrs. Paul E. McSween, Jr. Mr. and Mrs. David H. Meaden Mrs. Jo Lynne Meador CONTINUED ON PAGE 24

CIRCLES OF GIVING

CONTINUED FROM PAGE 23

Mr. Barry Meneck

Ms. Marti Raba

Mr. Patrick H. Swearingen, Jr.

Mr. and Mrs. Mitchell Meyer

Mr. and Mrs. James R. Reed

Mr. and Ms. John Sytsma

Mr. Eduardo Meza

Dr. and Mrs. Mark C. Rittenhouse

Dr. and Mrs. Alvin Thaggard III

Mr. Fred W. Middleton

Mr. and Mrs. Jeffrey A. Rochelle

Mr. Ron Thompson

Milam Real Estate Capital, LLC

Mr. and Mrs. Wallace Rogers III

Mr. and Mrs. Richard C. Traylor

Mr. and Mrs. Balous T. Miller

Mrs. Gerard T. Rote, Jr.

Mr. and Mrs. Robert E. Tucker, Jr.

Mr. and Mrs. Joe Miller

RSM US LLP

Mr. and Mrs. Arthur Uhl III

Ms. Prentice Huntington Miller

Mrs. Jay Lewis Rubin

Dr. and Mrs. George J. Vassar

Ms. LaRhesa Moon

Mr. and Mrs. Forrest Runnels, Jr.

Mr. and Mrs. Michael N. Venson

Mr. and Mrs. John Moorman

Mr. and Mrs. Frank Russell

Mr. and Mrs. Jack Vexler

Mr. and Mrs. Thomas Slick Moorman

Mr. and Mrs. McLean Douglas Russell

Jackson Walker, LLP

Mr. and Mrs. R. Hal Moorman IV

Mrs. Ruth Bowman Russell

Mr. and Mrs. Neill Bailey Walsdorf

Mrs. Jeffrey M. Morehouse

RVK Architects

Mr. and Mrs. Mark E. Watson III

Mr. and Mrs. Samuel J. Munafo

Dr. and Mrs. Larry S. Schlesinger

Mr. and Mrs. Conrad Weaver

Mr. S. Mark Murray

Mrs. H. Kyle Seale

Mr. and Mrs. Alex P. Weekes

Mr. and Mrs. Robert L. Myers IV

Mr. and Mrs. Edward C. Sealy

Mr. and Mrs. George Mitchell West

Mr. and Mrs. Scott Nathan

Mr. and Mrs. Donnie Seay

Ms. Kittie West

Mr. John Liston Nau III

Mr. and Mrs. Peter C. Selig

Whataburger

Mr. and Mrs. David F. Nicolson III

Mr. and Mrs. Robert Shaw

Dr. Alexis Wiesenthal

Mr. Robert Ochoa

Mrs. Clara Shovlin

Mr. and Mrs. Pat Wiggins

Mr. and Mrs. Steven M. Ogle

Mr. and Mrs. Pete Sitterle

Dr. and Mrs. W. Darrell Willerson, Jr.

Mrs. Frederic J. Oppenheimer

Ms. Emily Skillman

Mr. and Mrs. Jack Williams III

Mrs. Susan Oppenheimer

Dr. and Mrs. Lon S. Smith

Mr. and Mrs. James M. Wolff

Dr. and Mrs. Mahendra Patel

Mr. and Mrs. James B. Smith, Jr.

Mr. and Mrs. George J. Wommack

Mr. and Mrs. Henry B. Paup

Mr. and Mrs. John E. Smothers

Mr. and Mrs. Robert L. Worth, Jr.

Mr. Patrick J. Perron

Mr. J. E. Smothers, Jr.

Marsh Wortham

Mr. and Mrs. Christopher Petty

Mr. and Mrs. Stephen R. Spears

Mr. and Mrs. John G. Wright

Mr. and Mrs. John A. Peveto, Jr.

Mr. and Mrs. H. Leighton Steward

Mrs. Leon C. Wulfe, Jr.

Mr. and Mrs. Philip J. Pfeiffer

Mr. and Mrs. Stephen Stout

Mr. and Mrs. Peter Zacher

Mr. and Mrs. Alistair F. Philip

Mr. and Mrs. Matthew Strange

Mr. and Mrs. H. Bartell Zachry, Jr.

Mr. and Mrs. Phillip M. Plant

Mr. David J. Straus

Mr. and Mrs. Joshua Zeller

Mr. Vincent Porter and Dr. Cyndi Porter

Mr. and Mrs. John Steven Stroud

Mr. Thad M. Ziegler

Mr. and Mrs. Andrew B. Price

Mr. and Mrs. William Sutherland

Mr. and Mrs. William H. Quirk IV

Mr. and Mrs. Timothy L. Swan

FOR MORE INFORMATION ABOUT GIVING OPPORTUNITIES, PLEASE VISIT OUR WEBSITE WWW.TXBIOMED.ORG AND CLICK ON SUPPORT US. 24

TEX AS BIOMED FORUM

I THE WORK OF THE FORUM IS VITAL TO FUND THOSE IDEAS IN THE INCUBATOR STAGE SO THAT TEXAS BIOMED SCIENTISTS CAN CONTINUE DOWN THE PATH OF SCIENTIFIC DISCOVERY.

f you think about it, it’s nothing short of amazing that in 1970 – 50 years ago — Dottie Block, Tena Gorman and Ruth Eileen Sullivan had the vision and creativity to launch Southwest Research Forum, today known as Texas Biomedical Forum. How incredible is it that in our 50th year our mission is clearer than ever? There is nothing better than standing behind Texas Biomed at this moment in time.

The purpose of Texas Biomedical Forum continues to be to support the Texas Biomedical Research Institute through community relations, volunteer services and fundraising. Over the years, the Forum’s fundraising efforts have raised approximately $3.2 million in pilot studies. These grants are sometimes known as “seed grants” because they are relatively small, but the ideas they power can grow to become huge in their impact. The funding has allowed researchers to apply for additional grant monies exceeding $75 million in subsequent awards, which equates to approximately $23 in return for every single dollar of forum grants. In commemorating our 50th year, we received three $100,000 grant matches. We are incredibly grateful to the Gorman Family Foundation, the Mays Foundation and the Sullivan Family Foundation; the generosity of these three donor matches has allowed the Forum to give a little over $400,000 to the scientist pilot studies this year alone. We started our year with our Past President’s Luncheon. What an honor to be in the room with one of our Founders, Tena Gorman, as well as many founding board members and Past Presidents. This powerful group of women have each played a vital part in shaping this organization into what it is today. I am incredibly thankful for their continued support.

In November, we held our Fall Lecture Luncheon, one of our educational outreaches to the community. This series was on “Vaccinations: Myths and Misunderstandings” and the panel of speakers included Joanne Turner, Ph.D., Texas Biomed’s VP for Research and Cherise Rohr-Allegrini, President of the San Antonio Vaccine Development Center. Later in the month at our Margaritas, Mariachis & Members’ Social, our Forum members had the opportunity to listen to Dr. Mahesh Mohan discuss the effect of cannabinoids on the inflammation caused by HIV and potentially other illnesses as well. In February, the Forum hosted its 3rd and final Cheers for Chairity event. This event allowed some of the most talented designers in San Antonio and the surrounding area to redesign and put their creative twist on The Argyle’s historical dining chairs and patio furniture. This event was a huge success once again. At the beginning of March, we held our Spring Lecture Luncheon, where three lecture panelists, Suzanne Dabbous, M.D. (Radiologist and Past Forum President), Jean Patterson, Ph.D. (Professor) and Angelica M. Olmo-Fontanez, M.S. (Graduate Student/ Biomedical Researcher) discussed the “Routes of Success: From Early to Established Careers Women Discuss Pathways in STEM”. At this event, we also recognized the winners of our 26th Annual Science Education Awards. We’re very grateful to Valerie Guenther for her ongoing support of the Forum and her continued leadership with the Science Education Awards — a program that allows us to recognize top high school science teachers. Congratulations to Dr. Jamie Holbrook (Saint Mary’s Hall), Jennifer Rice (John Marshall High School), and Susan Barber (New Braunfels High School), who received the accolades this year. Last, but certainly not least, the Charles Butt Foundation presented a check for $50,000 to the Forum’s K-12 grant program. But the generosity didn’t stop there — the Foundation generously agreed to do so for three consecutive years. Another science outreach program the Forum offers is student tours. Throughout the year, San Antonio and surrounding area high school science classes get the privilege of touring the Texas Biomed campus. This year we had local students as well as neighboring towns including Del Rio High School, New Braunfels High School and Saint Mary’s Hall, to name just a few. 25

Whitney Schones and Karen Bryant present a $725,000 check from the 2020 Gala.

And then in the middle of March… an unexpected, and unwelcomed, pandemic: COVID-19. It goes without saying that we rapidly entered unchartered territory, confronted extraordinary and fast-moving circumstances, and faced some very tough decisions. On May 16th, our 50th Anniversary reception to honor the Forum’s Founders and Past Presidents was the first to be cancelled. Next, one of the most highly-anticipated social events of the year, held the first Saturday in May, our 50th Anniversary 2020 Forum Gala “The Starry Night” was cancelled. What has been made crystal clear in these uncertain times is the significance of the life-saving work and research carried out by Texas Biomed. With this in mind, we asked our table sponsors to consider allowing us to donate their sponsorship dollars intended for the 2020 gala directly to COVID-19 research. Through their generosity, we were able to give Texas Biomed close to $330,000 for this research, which is so critically needed at this time. As we close out this year with a gift of $800,000 to Texas Biomed, I’m overwhelmed with gratitude. Thank you to the Forum’s Board of Trustees and Advisors who worked so hard this year. Thank you to our Founders and Past Presidents for shaping us into what we are today and continuing to cheer us on along the way. Thank you to our members for supporting our cause. Thank you to our donors, who helped make this a record-breaking year. Most importantly, thank you to our leader Larry Schlesinger, M.D. and our scientists at Texas Biomed for making the world a better place one research project at a time — for making miraculous discoveries and saving countless lives along the way. I’m in awe of all of you and the part you played in this year’s success. It has been a true honor to have served as the 50th President of Texas Biomedical Forum. With Sincere Appreciation,

Amy Swaney presents Larry Schlesinger a check for $800,000, including the Gala funds, to support COVID-19 research, education programs and pilot projects.

Each year, The Forum awards grants to scientists at Texas Biomed to assist in developing preliminary data that will enable these scientists to secure future funding for novel projects. The following projects were funded in 2019.

FACULTY Assistant Professor Diako Ebrahimi, Ph.D. Population-specific gene splicing and its role in antiviral immunity

STAFF SCIENTIST Viraj Kulkarni, Ph.D. CRISPR/Cas13d RNA editing system: A new scissor to clip HIV RNA

POST-DOCTORAL SCIENTISTS Chrissy Leopold Wager, Ph.D. (works in Dr. Larry Schlesinger’s lab) Linking receptor-mediated phagocytosis and cAMP pathways in macrophage responses to tuberculosis Egie Enabulele, Ph.D. (works in Dr. Tim Anderson’s lab) Exploiting museum rodent collections to understand zoonotic disease reservoirs

COWLES POST-DOCTORAL FELLOWSHIP Amy Vogt Swaney 2019-2020 Forum President

Juan Ignacio Garcia, Ph.D. (works in Dr. Jordi Torrelles’ lab) Determining the efficacy of a novel TB diagnostic test to monitor treatment success in drug resistant TB cases

THE FOUNDER’S COUNCIL

2 THE FOUNDER’S COUNCIL EXISTS TO EDUCATE ITS MEMBERS ABOUT THE LIFE-CHANGING RESEARCH CONDUCTED EVERY DAY AT TEXAS BIOMED.

019 was a record setting year for The Founder’s Council as we were able to grant $143,500 for scientific equipment to Texas Biomedical Research Institute — an all-time high!

The Founder’s Council delivered three Lecture Luncheons at The Argyle throughout the year at which Texas Biomed scientists Dr. Deepak Kaushal, Dr. Raul A. Bastarrachea and Dr. Winka Le Clec’h shared their trailblazing research with our members and prospective members. In March of last year, members enjoyed our premiere event, Dining and Discourse, where scientists joined a table of guests in an intimate setting for dinner at The Argyle, allowing for candid conversations around their areas of expertise.

The Founder’s Council is a dynamic group of professionals and young leaders in San Antonio and are between the ages of 25 and 46. The Founder’s Council was founded in 1988 to honor the memory of Tom Slick and to promote Texas Biomedical Research Institute.

We are especially appreciative of event sponsors who underwrote 100 percent of our event costs, which allowed the Founder’s Council to contribute more substantially to our equipment grants. 2019 concluded with a Holiday Celebration and Grant Presentation at the home of Mr. and Mrs. Richard Azar and thanks to our membership and our generous sponsors and donors, I was honored to present Dr. Joanne Turner, Vice President for Research at Texas Biomed, with equipment grant awards totaling $143,500.

The mission of the Founder’s Council is to cultivate interest in Texas Biomed among young leaders in the greater San Antonio region who show potential for lifelong support of Texas Biomed. The Founder’s Council has approximately 300 members from all business sectors whose annual contributions and sponsorships help fund essential equipment grants for scientists at Texas Biomed. As President of the Founder’s Council, I was honored to be an ex-officio member of the Texas Biomed Board of Trustees. In these board meetings, I had the opportunity to witness the leadership, vision, and confidence that this distinguished group brings to Texas Biomed. How lucky we are in San Antonio to have a man like Dr. Larry Schlesinger leading a group of incredibly talented scientists, whose ground-breaking research will have lasting global impact for generations to come. In 2018, the Founder’s Council Board of Directors voted in favor of distributing fewer yet higher-value grants than in previous years. In 2019, our Board voted to once again distribute high-value scientific equipment grants which are able to be used by numerous scientists and across various research projects, thus making a greater impact at Texas Biomed.

This record year would not have been possible without the hard work of the incredible Board with whom I served, which included Aaron Asel, Michele Camp, Trey Dawson, Stephanie Dick, Burkley Fitzsimons, James Griffin, Andrew Hunt, Evan Ketabchi, Liz LaBarge, Trevor Lawton, Madison Marceau, Madison Mauze, Katie Reynolds, Robert Turnbull, Alexis Wiesenthal, and Clint Worth. I owe them an immense amount of gratitude for their dedication and service to Texas Biomed and Founder’s Council. The Founder’s Council exists to educate its members about life-changing research conducted every day at Texas Biomed. It is our sincerest hope, that once informed, these community leaders will continue to financially support Texas Biomed so that it may continue its noble and necessary research. This year played a crucial role in helping Texas Biomed make a global impact, and we are honored to carry on this distinguished tradition. I am eternally grateful for the trust placed in me to lead the Founder’s Council as President in 2019, and I look forward to the continued impact this group will make for Texas Biomed into the future. At the Service of Texas Biomed,

Callie Price, 2019 President, Founder’s Council

2019 FOUNDER’S COUNCIL

EXPLORERS

Mr. and Mrs. Evan Ketabchi

Mr. and Mrs. Robert Jones

Mr. and Mrs. Aaron Asel

Mr. and Mrs. Daniel Lasater

Mr. and Mrs. Phil Kandera

Mr. and Mrs. Richard N. Azar III

Mr. and Mrs. Charles Leddy

Mr. and Mrs. Clifton Karam

Mr. and Mrs. Jeff P. Bailey

Mr. Andrew J. Lewis IV

Ms. Ana Loretta Kerner

Mr. and Mrs. Jonathon Beitz

Mr. and Mrs. Ben Mathews

Mr. and Mrs. Barrett King

Mr. Matthew M. Bell

Mr. Krishna Reddy

Dr. and Mrs. Brian Langford

Ms. Brooke Benson

Ms. Katie Reynolds

Mr. and Mrs. Gregory Bolner

Mr. and Mrs. Paul A. Rohlfs, Jr.

Mr. Nicholas Mahrou and Ms. Lauren Miller

Mr. and Mrs. John Brozovich

Mr. and Mrs. Robert Webb Sellers, Jr.

Dr. and Mrs. Bryce Chandler

Mr. and Mrs. Robert Shaw

Mr. and Mrs. Trey Dawson

Mr. and Mrs. Paxton Jordan Smith

Mr. and Mrs. John W. Feik, Jr.

Mr. and Mrs. Robert Turnbull

Mr. and Mrs. Craig J. Garansuay

Mr. and Mrs. R. Bruce Walker

Mr. and Mrs. Jared and Brooke Meabon

MEMBERS

Mr. and Mrs. Brian O’Gorman

Mr. and Mrs. Evan Gerald Mr. Jonathan Hess Mr. and Mrs. Andrew Hunt Mr. and Mrs. Tony C. Johnson Mr. Trevor Lawton and Ms. Amy Stinston Mr. and Mrs. Byron L. LeFlore, Jr. Mr. and Mrs. Madison C. Marceau Mr. and Mrs. David Mauze Mr. and Mrs. Madison Mauze Mr. and Mrs. Chance Mazurek Ms. Prentice Huntington Miller Mr. and Mrs. Robert L. Myers IV Mr. and Mrs. Scott Nathan Mr. and Mrs. Gardner Peavy Mr. and Mrs. Andrew B. Price Mr. and Mrs. Jeffrey de Rojas Dr. Alexis Wiesenthal

Mr. and Mrs. Landon Anderson Mr. Suhail Arastu Mr. and Mrs. Scott Archer Mr. and Mrs. Joe Ashby Mr. and Mrs. Brian Ballantyne Mr. and Mrs. Edward Bartolomei Mr. and Mrs. Brad Beldon Mr. and Mrs. Josh Berg Mr. Kyle Braaten Mr. and Mrs. C. Dawson Bremer Mr. Jeffrey Brouillard Ms. Michele Camp Dr. and Mrs. McCurdy Cardwell Mr. and Mrs. Andrew Cardwell Mr. and Mrs. Stuart Carter Mr. Robert M. Cavender Jr.

Mr. and Mrs. Colby Lewis Mr. and Mrs. Alcide M. Longoria Mr. and Mrs. Peter Mako Mr. Robert T. McCullough Mr. and Mrs. Sergio Montemayor Mr. and Mrs. Ross Ormond Mr. and Mrs. Kyle Palmer Mr. Benjamin Pilgrim Mr. and Mrs. Jack Marshall Porterfield Mr. and Mrs. J.B. Richter Judge Carla Martinez Riedl Mr. and Mrs. Will Rogers Mr. and Mrs. Patrick Rouse Mr. and Mrs. Stephen Schneider Mr. Jonathon R. Schneider Mr. and Mrs. Bryan Schones Mr. and Mrs. Jacob Schweers Mr. and Mrs. Wes Sharples Mr. and Ms. John Sytsma Mr. and Mrs. Frederick Thomson IV Mr. Robert Thomure

Mr. and Mrs. George J. Wommack

Mr. and Mrs. James Chandler

ADVENTURERS

Dr. Susie DeKoch

Mr. and Mrs. Edward Badouh III

Mr. Will Fawcett

Mr. J. Craig Browning, Jr.

Mr. and Mrs. Ryan Griffin

Mr. and Mrs. Jonny Fitzsimons

Mr. and Mrs. Roger C. Hill III

Mr. and Mrs. William Daniel Westmoreland

Mr. Sean Galligan

Mr. and Mrs. David Hornberger

Mr. and Mrs. Marc Whyte

Mr. and Mrs. James B. Griffin

Mr. and Mrs. Anson Howard

Dr. Alison Wiesenthal

Mr. and Mrs. Brandon E. Grossman

Dr. Joe Johnston

Mr. and Mrs. James Y. Williams

Ms. Kalyn Davidson

Mr. Hunter Thunell Mr. and Mrs. Matt Toohey Mr. and Mrs. Bart Waters

Mr. and Mrs. Robert Watson, Jr.

RVK Architects Mr. Jason Puchot Mr. Heath Wenrich

Marsh Wortham Ms. Katie Loftin Mr. Hunter Hawkins

Texas Medical Legal Consultants, LLC Mrs. Elizabeth T. LaBarge, Esq.

Mauze Construction Mr. David Mauze

CORPORATE

Whataburger Mrs. Linda Benavides Ms. Kim Harle

McNelis + Associates, PLLC Mr. Sean B. McNelis Mr. Richard McSwain

Articulate Strategic Communications Ms. LaRhesa Moon